US says Teva antidepressant is ineffective

October 3, 2012 by Matthew Perrone in Medications

(AP)—Teva Pharmaceuticals has stopped shipping its generic version of a popular antidepressant off the market after a U.S. government analysis showed the pill does not work properly.

The said Wednesday it asked Teva to withdraw Budeprion XL 300 after new testing showed the releases its key ingredient faster than the original drug Wellbutrin XL 300, made by .

A spokeswoman for Teva said the company stopped shipping the drug last Thursday.

The action contradicts the FDA's previous update on the issue in 2008, when regulators said the drugs are essentially the same. That review came after hundreds of patients complained that Teva's drug did not work as well or caused side effects like headaches, anxiety and .

In 2007, the website ConsumerLab published an analysis of the two drugs, indicating Budeprion XL released 34 percent of its in just two hours, compared to 8 percent for the original drug. ConsumerLab is a small privately-held company that independently teswsts drugs and nutrition products.

"We're proud we were able to help uncover this problem, but it's unfortunate that it's taken the FDA five years to get the product removed," said Dr. Tod Cooperman, president of ConsumerLab. "I believe the majority of generics are fine but there are certainly situations where some aren't equivalent."

Generic drugs approved by the FDA are required to be chemically equivalent to the original products, producing the same medical effects in patients.

The FDA said Wednesday that its initial, incorrect ruling was based on tests of the 150 milligram version of Budeprion, under the assumption those results would also apply to the 300 milligram version. The agency said that approach "is no longer appropriate."

"Based on the information we had available at that time we concluded that the 150 milligram strength was doing what it should, and that it was acceptable to extrapolate those findings to the 300 milligram strength" said Barbara Davit, director of bioequivalence for FDA's office of generic drugs. Agency officials said they decided to perform their own study after continuing to receive complaints about Budeprion XL 300.

The FDA said it completed its study of the two drugs in 24 adult patients in August, and notified Teva of the findings last month.

"The role of patients and health care professionals in sharing their experiences with generic versions of Wellbutrin XL 300 mg contributed to further studies, which led to this action," said Dr. Gregory Geba, the FDA's director for generic drug.

Wellbutrin, known chemically as buprion, is prescribed to treat depression, anxiety and symptoms of nicotine withdrawal.

The FDA approved the first generic versions of Wellbutrin XL in 2006. Most doctors switch patients from branded drugs to cheaper when they become available, since can cost between 30 to 80 percent less.

Budeprion XL is a once-a-day pill made by U.S.-based Impax Laboratories Inc. and sold by Israel-based Teva Pharmaceutical Industries Ltd.

"FDA's guidance affects the bioequivalence rating of the product and does not reflect any safety issue," said Denise Bradley. "Teva's first priority is to our patients and providing them with quality medicines."

Four other generic drugmakers market 300 milligram versions of Wellbutrin: Anchen, Actavis, Watson and Mylan. The FDA has not tested the equivalence of those drugs, but said it has requested the drugmakers conduct their own studies and submit them to the agency by March 2013.

FDA officials said patients taking the 300 milligram dose of Budepion account for just 2 percent of the U.S. market for the drug.

Copyright 2012 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

5 /5 (1 vote)  

Rank 5 /5 (1 vote)
Related Stories
Relevant PhysicsForums posts

More news stories

Experts favor US approval of Merck sleeping pill (Update)

An independent panel of experts on Wednesday recommended US approval of a new Merck sleeping pill called suvorexant, but expressed concerns over the highest dosage and risks of drowsy daytime driving.

Medications created 17 hours ago | popularity not rated yet | comments 0

Glaxo, US partnering to develop new antibiotics

GlaxoSmithKline PLC says it's starting an unusual collaboration with the U.S. government to develop several antibiotics for both bioterrorism threats and bacterial infections resistant to current medicines.

Medications created 19 hours ago | popularity not rated yet | comments 0

Study finds new pneumococcal vaccine appears to be as safe as previously used vaccine

The new 13-valent pneumococcal conjugate vaccine (PCV13) appears to be as safe as the previous version used prior to 2010, the 7-valent pneumococcal conjugate vaccine (PCV7), according to a Kaiser Permanente study published ...

Medications created May 22, 2013 | popularity not rated yet | comments 0

Succesful results in developing oral vaccine against diarrhea

The University of Gothenburg Vaccine Research Institute (GUVAX) announces successful results in a placebo controlled phase I study of an oral, inactivated Escherichia coli diarrhea vaccine.

Medications created May 22, 2013 | popularity not rated yet | comments 0

New sleeping pill poised to hit US markets

An experimental sleeping pill from US drug company Merck is effective at helping people fall and stay asleep, according to reviewers at the US Food and Drug Administration, which could soon approve the new drug.

Medications created May 21, 2013 | popularity 4.2 / 5 (5) | comments 0


Researchers suggest boosting body's natural flu killers

A known difficulty in fighting influenza (flu) is the ability of the flu viruses to mutate and thus evade various medications that were previously found to be effective. Researchers at the Hebrew University of Jerusalem have ...

Second-generation TAVI device—Lotus Valve—shows good performance in REPRISE II

22 May 2013, Paris, France: The Lotus Valve, a second-generation transcatheter aortic valve implantation (TAVI) device, was successfully implanted in all of the first 60 patients in results from REPRISE II reported at EuroPCR ...

Major human drug trial underway for Alzheimer's

A potentially ground-breaking human drug trial is currently underway, which aims to discover whether blood pressure medication can slow or halt the progression of Alzheimer's Disease (AD). This is the latest ...

Pay attention: How we focus and concentrate

Scientists at Newcastle University have shed new light on how the brain tunes in to relevant information.

New discovery in fight against deadly meningococcal disease

Professor Michael Jennings, Deputy Director of the Institute for Glycomics at Griffith University, was part of an international team that discovered the previously unknown pathway of how the bacterium colonizes people.

Are kids who take music lessons different from other kids?

(Medical Xpress)—Research by U of T Mississauga psychology professor Glenn Schellenberg reveals that two key personality traits – openness-to-experience and conscientiousness—predict better than IQ ...